0001209191-22-003062.txt : 20220112 0001209191-22-003062.hdr.sgml : 20220112 20220112163521 ACCESSION NUMBER: 0001209191-22-003062 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220111 FILED AS OF DATE: 20220112 DATE AS OF CHANGE: 20220112 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Fischesser Ryan CENTRAL INDEX KEY: 0001871155 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40631 FILM NUMBER: 22526969 MAIL ADDRESS: STREET 1: CARIBOU BIOCIENCES, INC. STREET 2: 2929 7TH STREET, SUITE 105 CITY: BERKELEY STATE: CA ZIP: 94710 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Caribou Biosciences, Inc. CENTRAL INDEX KEY: 0001619856 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 453728228 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2929 7TH STREET, SUITE 105 CITY: BERKELEY STATE: CA ZIP: 94710 BUSINESS PHONE: 510-982-6030 MAIL ADDRESS: STREET 1: 2929 7TH STREET, SUITE 105 CITY: BERKELEY STATE: CA ZIP: 94710 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-01-11 0 0001619856 Caribou Biosciences, Inc. CRBU 0001871155 Fischesser Ryan C/O CARIBOU BIOSCIENCES, INC. 2929 7TH STREET, SUITE 105 BERKELEY CA 94710 0 1 0 0 VP of Finance and Controller Common Stock 2022-01-11 4 P 0 569 2.69 A 102264 D Common Stock 2022-01-11 4 P 0 6818 4.11 A 109082 D Option to purchase Common Stock 2.69 2022-01-11 4 X 0 569 0.00 D 2029-03-18 Common Stock 569 6815 D Option to purchase Common Stock 4.11 2022-01-11 4 X 0 6818 0.00 D 2031-03-29 Common Stock 6818 20452 D These shares were acquired pursuant to the exercise of a stock option, as reported in Table II below. The exercise price for this stock option was incorrectly reported as $2.68 per share on the reporting person's Form 3 filed on July 23, 2021. The shares subject to this option have vested or will vest in equal monthly installments until the option is fully vested on January 1, 2023, subject to the reporting person's continued service to the Issuer through the applicable vesting dates. 1/4th of the shares subject to this option vested on January 1, 2022 and an additional 1/48th of the aggregate number of shares subject to the option have vested or will vest on the corresponding day of each month thereafter, subject to the reporting person's continued services to the Issuer through the applicable vesting dates. /s/ Barbara G. McClung, as attorney-in-fact 2022-01-12